Form 4: Royalty Pharma EVP Sells 20,000 Shares Under 10b5-1 Plan

Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, sold 20,000 Class A Ordinary Shares for over $41 per share as part of a pre-arranged trading plan.

Summary

• Marshall Urist, Executive Vice President of Research & Investments at Royalty Pharma plc, sold 20,000 Class A Ordinary Shares.
• The sale occurred on January 30, 2026, at a weighted average price of $41.0905 per share, with individual transactions ranging from $40.88 to $41.28.
• This transaction was executed under a Rule 10b5-1 trading plan adopted on September 16, 2025.
• Following the sale, Mr. Urist directly holds 7,398 Class A Ordinary Shares and indirectly holds 19,020 Class A Ordinary Shares through an IRA.
• Additionally, Mr. Urist and family vehicles control limited partnership interests exchangeable into 2,474,120 Class A Ordinary Shares and 1,356,528 Class E Ordinary Shares (subject to vesting conditions).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction under a pre-established plan, which typically has a neutral to slightly negative sentiment due to the reduction in direct executive ownership, but is not indicative of new adverse company developments.

Positives

• The sale was conducted under a pre-arranged 10b5-1 trading plan, indicating it was not based on new, non-public information.
• Despite the sale, Mr. Urist retains significant beneficial ownership, including direct holdings, IRA holdings, and substantial exchangeable partnership interests totaling over 3.8 million shares.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the direct equity stake of a key executive in the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider sales, even under 10b5-1 plans, are routinely monitored by investors for potential signals regarding management's confidence. However, the pre-arranged nature of this sale typically mitigates concerns that it is based on new, negative material information, aligning with standard executive compensation and liquidity management practices in the pharmaceutical royalty sector.

Comparison to Industry Standards

• Not applicable for this type of insider transaction filing.

Related Party Transactions

• The sale of shares by an executive officer (Marshall Urist) constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May observe a slight reduction in direct executive alignment, but the 10b5-1 plan and substantial remaining holdings temper any negative interpretation.
• Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this filing.

Key Dates

Recommendation

The insider sale, while reducing direct executive ownership, was conducted under a pre-arranged 10b5-1 plan, which suggests it is for personal financial planning rather than a reaction to new company-specific information. The executive retains substantial indirect and exchangeable interests. Therefore, this transaction alone does not warrant a change in investment thesis, leading to a 'hold' recommendation.

Keywords

Royalty Pharma, RPRX, Marshall Urist, Insider Sale, Form 4, 10b5-1 Plan, Executive Stock Sale, Class A Ordinary Shares, Equity Transaction